Literature DB >> 21668629

Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy.

A Loupy1, A Cazes, R Guillemain, C Amrein, A Hedjoudje, M Tible, V Pezzella, J N Fabiani, C Suberbielle, D Nochy, G S Hill, J P Empana, X Jouven, P Bruneval, J P Duong Van Huyen.   

Abstract

In heart transplants, the significance of very late rejection (after 7 years post-transplant, VLR) detected by routine endomyocardial biopsies (EMB) remains uncertain. Here, we assessed the prevalence, histopathological and immunological phenotype, and outcome of VLR in clinically stable patients. Between 1985 and 2009, 10 662 protocol EMB were performed at our institution in 398 consecutive heart transplants recipients. Among the 196 patients with >7-year follow-up, 20 (10.2%) presented subclinical ≥3A/2R-ISHLT rejection. The VLR group was compared to a matched control group of patients without rejection. All biopsies were stained for C4d/C3d/CD68 with sera screened for the presence of donor-specific antibodies (DSAs). In addition to cellular infiltrates with myocyte damage, 60% of VLR patients had evidence of intravascular macrophages. C4d and/or C3d-capillary deposition was found in 55% VLR EMB. All cases of VLR associated with microcirculation injury had DSAs (mean DSA(max) -MFI = 1751 ± 583). This entity was absent from the control group (p < 0.0001). Finally, after a similar follow-up postreference EMB of 6.4 ± 1 years, the mean of CAV grade was 0.76 ± 0.18 in the control group compared to 2.06 ± 0.26 in the VLR group respectively, p = 0.001). There was no difference in patient survival between study and control groups. In conclusion, VLR is frequently associated with complement-cascade activation, microvascular injury and DSA, suggesting an antibody-mediated process. VLR is associated with a dramatic progression to severe CAV in long-term follow-up. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668629     DOI: 10.1111/j.1600-6143.2011.03563.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  21 in total

Review 1.  B cells in cardiac transplants: from clinical questions to experimental models.

Authors:  William M Baldwin; Marc K Halushka; Anna Valujskikh; Robert L Fairchild
Journal:  Semin Immunol       Date:  2011-09-19       Impact factor: 11.130

2.  Banff 2011 Meeting report: new concepts in antibody-mediated rejection.

Authors:  M Mengel; B Sis; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; L Cendales; A J Demetris; C B Drachenberg; C F Farver; E R Rodriguez; W D Wallace; D Glotz
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

3.  Cardiac allograft vasculopathy: a complex multifactorial sequela of heart transplantation.

Authors:  Ana Maria Segura; L Maximilian Buja
Journal:  Tex Heart Inst J       Date:  2013

4.  Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo.

Authors:  N M Valenzuela; L Hong; X-Da Shen; F Gao; S H Young; E Rozengurt; J W Kupiec-Weglinski; M C Fishbein; E F Reed
Journal:  Am J Transplant       Date:  2012-12-27       Impact factor: 8.086

5.  Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus.

Authors:  Rosie Qin; April Ks Salama
Journal:  Melanoma Manag       Date:  2015-11-24

Review 6.  Blood-based immunological monitoring after heart transplant. Current status and future prospects.

Authors:  Jignesh K Patel
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-03-02

7.  Airway hypoxia in lung transplantation.

Authors:  Shravani Pasnupneti; Mark R Nicolls
Journal:  Curr Opin Physiol       Date:  2018-12-13

Review 8.  Coronary cardiac allograft vasculopathy versus native atherosclerosis: difficulties in classification.

Authors:  Annalisa Angelini; Chiara Castellani; Marny Fedrigo; Onno J de Boer; Lorine B Meijer-Jorna; Xiaofei Li; Marialuisa Valente; Gaetano Thiene; Allard C van der Wal
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

Review 9.  Transplantation tolerance and its outcome during infections and inflammation.

Authors:  Anita S Chong; Maria-Luisa Alegre
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

10.  Evolving concepts and treatment strategies for cardiac allograft vasculopathy.

Authors:  Rodolfo Denadai Benatti; David O Taylor
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.